


FILE ORDERING
order patent files results

P Friday (TGIF)
4/11/03
3:05:59 PM
WFO1003PR

Serial# 09/606717 File order accepted

Place another order



G1 Ph,Cb,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:46:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1295 TO ITERATE

77.2% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

5 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 23742 TO 28058
PROJECTED ANSWERS: 5 TO 281

L2 5 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 14:46:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 25377 TO ITERATE

100.0% PROCESSED 25377 ITERATIONS
SEARCH TIME: 00.00.01

79 ANSWERS

L3 79 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
148.15	148.36

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 14:46:51 ON 11 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

Habte

4/11/2003

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Apr 2003 VOL 138 ISS 16
FILE LAST UPDATED: 10 Apr 2003 (20030410/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 2 L3

=> d ibib abs hitstr tot


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:449662 CAPLUS
 DOCUMENT NUMBER: 137:33310
 TITLE: Preparation of anilinothiazopyrimidines as IKK inhibitors
 INVENTOR(S): Koia, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 194 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046171	A2	20020613	WO 2001-US46403	20011205
WO 2002046171	A3	20030123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG


AU 2002020195 A5 20020618 AU 2002-20195 20011205
 PRIORITY APPLN. INFO.: US 2000-251816P P 20001206
 WO 2001-US46403 W 20011205

OTHER SOURCE(S): MARPAT 137:33310
 GI




AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of 1.0 μM in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434944-92-0 CAPLUS
 CN Benzamide, 4-[[4-[(2-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-96-4 CAPLUS
 CN Benzamide, 4-[[4-[(3-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-99-7 CAPLUS
 CN Benzamide, 4-[[4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-00-3 CAPLUS
 CN Benzamide, 4-[[4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

Habte

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)

more compds. of the above compds.
 IT 434944-90-8P 434944-91-9P 434944-92-0P
 434944-96-4P 434944-99-7P 434945-00-3P
 434945-01-4P 434945-04-7P 434945-05-8P
 434945-27-4P 434945-75-2P 434945-76-3P
 434949-28-7P 434949-29-8P 434949-31-2P
 434949-33-4P 434949-35-6P 434949-36-7P
 434949-38-9P 434949-40-3P 434949-42-5P
 434949-44-7P 434949-47-0P 434949-50-5P
 434949-53-8P 434949-56-1P 434949-68-5P
 434949-71-0P 434949-74-3P 434949-77-6P
 434949-79-8P 434949-81-2P 434949-83-4P
 434949-85-6P 434949-87-8P 434949-91-4P
 434949-94-7P 434949-95-8P 434949-96-9P
 434949-97-0P 434949-98-1P 434949-99-2P
 434950-03-5P 434950-04-6P 434950-05-7P
 434950-06-8P 434950-07-9P 434950-08-0P
 434950-09-1P 434950-10-4P 434950-11-5P
 434950-12-6P 434950-13-7P 434950-14-8P
 434950-15-9P 434950-33-1P 434950-34-2P
 434950-35-3P 434950-36-4P 434950-37-5P
 434950-38-6P 434950-39-7P 434950-40-0P
 434950-41-1P 434950-42-2P 434950-43-3P
 434950-44-4P 434950-45-5P 434950-46-6P
 434950-47-7P 434950-48-8P 434950-49-9P
 434950-50-2P 434950-51-3P 434950-52-4P
 434950-53-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of anilinothiazopyrimidines as IKK inhibitors)

RN 434944-90-8 CAPLUS

CN Benzamide,


4-[[4-[(4-chlorophenyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-91-9 CAPLUS
 CN Benzamide, 4-[[4-[(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)

CRN 434944-99-7
 CMF C23 H25 N5 O3 S




CM 2


CRN 76-05-1
 CMF C2 H3 O2



RN 434945-01-4 CAPLUS
 CN Benzamide, 4-[[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434945-04-7 CAPLUS
 CN Benzamide, 4-[[4-[(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




4/11/2003


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 434945-05-8 CAPLUS
 CN Benzanide, 4-[[4-(4-(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434945-27-4 CAPLUS
 CN Morpholine, 4-[[4-(4-(4-(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434945-75-2 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-(4-(4-(pyridinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434945-76-3 CAPLUS
 CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-(4-(4-(pyridinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-28-7 CAPLUS

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-35-6 CAPLUS
 CN Piperazine, 3-methyl-1-[[4-(4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434949-36-7 CAPLUS
 CN 1-Piperazinepropanamine, N,N-dimethyl-4-[[4-(4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-38-9 CAPLUS
 CN Piperazine, 1-[[4-(4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-4-(2-oxo-2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-(4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-29-8 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-(4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-31-2 CAPLUS
 CN Piperazine, 1-[[4-(4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-33-4 CAPLUS
 CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[[4-(4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A



RN 434949-40-3 CAPLUS
 CN 4-Piperidinol, 1-[[4-(4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-42-5 CAPLUS
 CN Piperidine, 1-[[4-(4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Habte

4/11/2003

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A




RN 434949-44-7 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A



RN 434949-68-5 CAPLUS
 CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[[4-(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-71-0 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[[4-(4-hydroxy-1-


Habte

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 434949-47-0 CAPLUS
 CN Piperazine, 1-(2,2-dimethyl-1-oxopropyl)-4-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-50-5 CAPLUS
 CN Piperazine, 1-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 434949-53-8 CAPLUS
 CN Piperazine, 1-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-4-(1-oxobutyl)- (9CI) (CA INDEX NAME)




RN 434949-56-1 CAPLUS
 CN Piperazine, 1-[[3,5-dimethyl-4-isoxazolyl]carbonyl]-4-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)
 piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-74-3 CAPLUS
 CN Piperazine, 1-[4-[[4-[[4-(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-77-6 CAPLUS
 CN Piperidine, 1-[4-[[4-[[4-(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 434949-79-8 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[[4-(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-81-2 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[[4-(4-acetyl-1-piperazinyl)sulfonyl]phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

4/11/2003


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-83-4 CAPLUS
 CN 4-(4-(2-((4-(4-acetyl-1-piperazinyl)carbonyl)phenyl)amino)-4-pyrimidinyl)phenyl)sulfonyl-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 434949-85-6 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-87-8 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(1-pyrrolidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-95-8 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(2-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-96-9 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-97-0 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(3-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-98-1 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(3-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-91-4 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-94-7 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(1-hexahydro-1H-azepin-1-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-99-2 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-03-5 CAPLUS
 CN Piperazine, 1-[[4-[[4-(1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-04-6 CAPLUS
 CN Piperazine, 1-[[4-[[4-(1-pyrrolidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-05-7 CAPLUS
 CN Piperazine, 3,5-dimethyl-1-[[4-[[4-(1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


4/11/2003

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


Relative stereochemistry.



RN 434950-06-8 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl - (9CI) (CA
INDEX
NAME)




RN 434950-07-9 CAPLUS
CN Piperazine,
1-(2-ethoxyethyl)-4-[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-
pyrimidinyl]aminobenzoyl]- (9CI) (CA INDEX NAME)




RN 434950-08-0 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-{{4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino}benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-11-5 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-{4-(1-pyrrolidinyl)sulfonyl}phenyl]-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)




RN 434950-12-6 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA
INDEX
NAME)




RN 434950-13-7 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-09-1 CAPLUS
CN Piperazine,
1-(2-ethoxyethyl)-4-[4-[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-
2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-10-4 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[4-(1-pyrrolidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


Relative stereochemistry.




```

RN      434950-14-8  CAPLUS
CN      Piperazine,
1-(2-ethoxyethyl)-4-[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-
pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


```



RN 434950-15-9 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA
INDEX
NAME)




RN 434950-33-1 CAPLUS
CN 1-Piperazinepropenamine,
N,N-dimethyl-4-[4-[[4-[[[tetrahydro-2H-pyran-4-
yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



4/11/2003


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-34-2 CAPLUS
 CN 4-Piperidinol, 1-[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-35-3 CAPLUS
 CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-39-7 CAPLUS
 CN Piperazine, 3-methyl-1-[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434950-40-0 CAPLUS
 CN Piperidine, 4-[(1-pyrrolidinyl)-1-[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-41-1 CAPLUS
 CN 4-Piperidinol, 1-[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-42-2 CAPLUS
 CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


Habe

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 2-A




RN 434950-36-4 CAPLUS
 CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-37-5 CAPLUS
 CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-38-6 CAPLUS
 CN Piperazine, 1-[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A




RN 434950-43-3 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-44-4 CAPLUS
 CN Piperazine, 1-[4-[[4-[(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


4/11/2003

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-45-5 CAPLUS

CN Piperazine, 1-(2-ethoxyethyl)-4-[[4-[(4-(phenylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-46-6 CAPLUS

CN Piperazine, 1-methyl-4-[[4-[(4-(phenylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl]-4-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 434950-47-7 CAPLUS

CN Piperazine, 1-acetyl-4-[[4-[(4-(phenylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-52-4 CAPLUS

CN Benzamide, N-(4-hydroxycyclohexyl)-4-[[4-[(4-(phenylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-53-5 CAPLUS

CN Benzamide, N,N-dimethyl-4-[[4-[(4-(phenylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




IT 434950-65-9P 434950-68-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of anilino-pyrimidines as IKK inhibitors)

RN 434950-65-9 CAPLUS

CN Benzoic acid, 4-[[4-[(4-(morpholinylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-68-2 CAPLUS

CN Benzoic acid, 4-[[4-[(4-(tetrahydro-2H-pyran-4-yl)sulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 434950-48-8 CAPLUS

CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[(4-(phenylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-49-9 CAPLUS

CN Piperazine, 1-methyl-4-[[4-[(4-(phenylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-50-2 CAPLUS

CN Piperazine, 1-methyl-4-[[4-[(4-(phenylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 434950-51-3 CAPLUS

CN 1-Piperazinepropanamine, N,N-dimethyl-4-[[4-[(4-(phenylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:449661 CAPLUS
 DOCUMENT NUMBER: 137:33309
 TITLE: Preparation of anilino pyrimidines as JNK pathway inhibitors
 INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitake; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 199 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046170	A2	20020613	WO 2001-US46402	20011205

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002027214 A5 20020618 AU 2002-27214 20011205
 PRIORITY APPLN. INFO.: US 2000-251904 P 20001206
 WO 2001-US46402 W 20011205
 OTHER SOURCE(S): MARPAT 137:33309
 GI




AB The title compds. [I: R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepd. E.g., a multi-step synthesis of 1 [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of 10 nM in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns.


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434944-92-0 CAPLUS
 CN Benzamide, 4-[[4-[(2-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-96-4 CAPLUS
 CN Benzamide, 4-[[4-[(3-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-99-7 CAPLUS
 CN Benzamide, 4-[[4-[(1-methyl-4-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-00-3 CAPLUS
 CN Benzamide, 4-[[4-[(1-methyl-4-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

Habte

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)
 contg. one or more compds. of the above compds.

IT 434944-90-8P 434944-91-9P 434944-92-0P
 434944-96-4P 434944-99-7P 434945-00-3P
 434945-01-4P 434945-04-7P 434945-05-8P
 434945-27-4P 434945-75-2P 434945-76-3P
 434945-28-7P 434945-29-8P 434945-31-2P
 434945-33-4P 434945-35-6P 434945-36-7P
 434945-38-9P 434945-40-3P 434945-42-5P
 434945-44-7P 434945-47-0P 434945-50-5P
 434945-53-8P 434945-56-1P 434945-68-5P
 434945-71-0P 434945-74-3P 434945-77-6P
 434945-79-8P 434945-81-2P 434945-83-4P
 434945-85-6P 434945-87-8P 434945-91-4P
 434945-94-7P 434945-95-8P 434945-96-9P
 434945-97-0P 434945-98-1P 434945-99-2P
 434950-03-5P 434950-04-6P 434950-05-7P
 434950-06-8P 434950-07-9P 434950-08-0P
 434950-09-1P 434950-10-4P 434950-11-5P
 434950-12-6P 434950-13-7P 434950-14-8P
 434950-15-9P 434950-16-1P 434950-17-2P
 434950-18-3P 434950-19-4P 434950-20-5P
 434950-21-6P 434950-22-7P 434950-23-8P
 434950-24-9P 434950-25-0P 434950-26-1P
 434950-27-2P 434950-28-3P 434950-29-4P
 434950-30-5P 434950-31-6P 434950-32-7P
 434950-33-8P 434950-34-9P 434950-35-0P
 434950-36-1P 434950-37-2P 434950-38-3P
 434950-39-4P 434950-40-5P 434950-41-6P
 434950-42-7P 434950-43-8P 434950-44-9P
 434950-45-0P 434950-46-1P 434950-47-2P
 434950-48-3P 434950-49-4P 434950-50-5P
 434950-51-6P 434950-52-7P 434950-53-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of anilino pyrimidines as JNK pathway inhibitors)

RN 434944-90-8 CAPLUS

CN Benzamide,

4-[[4-[(4-chlorophenyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434944-91-9 CAPLUS

CN Benzamide,

4-[[4-[(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)

CRN 434944-99-7
 CMP C23 H25 N5 O3 S



CM 2


CRN 76-05-1
 CMP C2 H F3 O2



RN 434945-01-4 CAPLUS

CN Benzamide,


4-[[4-[(4-methyl-1-piperazinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-04-7 CAPLUS


CN Benzamide,

4-[[4-[(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




4/11/2003


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 434945-05-8 CAPLUS
 CN Benzamide, 4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434945-27-4 CAPLUS
 CN Morpholine, 4-[4-[[4-(4-(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434945-75-2 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-(4-(4-pyridinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434945-76-3 CAPLUS
 CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-(4-(4-pyridinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-28-7 CAPLUS

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-35-6 CAPLUS
 CN Piperazine, 3-methyl-1-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434949-36-7 CAPLUS
 CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-38-9 CAPLUS
 CN Piperazine, 1-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-29-8 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-31-2 CAPLUS
 CN Piperazine, 1-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-33-4 CAPLUS
 CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A



RN 434949-40-3 CAPLUS
 CN 4-Piperidinol, 1-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-42-5 CAPLUS
 CN Piperidine, 1-[4-[[4-(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Habte

4/11/2003


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 2-A

RN 434949-44-7 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-9CI (CA INDEX NAME)




L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A



RN 434949-68-5 CAPLUS
 CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-(4-hydroxy-1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-9CI (CA INDEX NAME)




RN 434949-71-0 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-hydroxy-1-


Habe

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 434949-47-0 CAPLUS
 CN Piperazine, 1-(2,2-dimethyl-1-oxopropyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-9CI (CA INDEX NAME)



RN 434949-50-5 CAPLUS
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxobutyl)-9CI (CA INDEX NAME)




RN 434949-53-8 CAPLUS
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxobutyl)-9CI (CA INDEX NAME)




RN 434949-56-1 CAPLUS
 CN Piperazine, 1-[[3,5-dimethyl-4-isoxazolyl]carbonyl]-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-9CI (CA INDEX NAME)


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)
 piperidinylsulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-9CI (CA INDEX NAME)




RN 434949-74-3 CAPLUS
 CN Piperazine, 1-[[4-[[4-(4-hydroxy-1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-9CI (CA INDEX NAME)



RN 434949-77-6 CAPLUS
 CN Piperidine, 1-[[4-[[4-(4-hydroxy-1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)-9CI (CA INDEX NAME)




RN 434949-79-8 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-methyl-1-piperazinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-9CI (CA INDEX NAME)




RN 434949-81-2 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-methyl-1-piperazinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-9CI (CA INDEX NAME)

4/11/2003


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-83-4 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[[4-[2-[[4-[[4-(4-acetyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 434949-85-6 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-87-8 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-95-8 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-96-9 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[(4-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-97-0 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[(3-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-98-1 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[(3-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Habe

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-91-4 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[(1-pyrrolidinyl)-1-piperidinyl]sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-94-7 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[(1-hexahydro-1H-azepin-1-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-99-2 CAPLUS
 CN Piperazine, 1-acetyl-4-[4-[[4-[(1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-03-5 CAPLUS
 CN Piperazine, 1-[4-[[4-[(1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-04-6 CAPLUS
 CN Piperazine, 1-[4-[[4-[(1-pyrrolidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-05-7 CAPLUS
 CN Piperazine, 3,5-dimethyl-1-[4-[[4-[(1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


4/11/2003

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


Relative stereochemistry.



RN 434950-06-8 CAPLUS
 CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-(1-
 piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA
 INDEX
 NAME)




RN 434950-07-9 CAPLUS
CN Piperazine,
1-(2-ethoxyethyl)-4-[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-
pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-08-0 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-11-5 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-12-6 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA
INDEX
NAME)




RN 434950-13-7 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-09-1 CAPLUS
CN Piperazine.
1-(2-ethoxyethyl)-4-[4-[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-
2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-10-4 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[1-pyrrolidinylsulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


Relative stereochemistry.




RN 434950-14-8 CAPLUS
CN Piperazine,
1-(2-ethoxyethyl)-4-[4-{{4-[4-(4-morpholinyl)sulfonyl]phenyl}-2-
pyrimidinyl}amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-15-9 CAPLUS
 CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-[4-(4-morpholinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA
 INDEX NAME)



RN 434950-33-1 CAPLUS
CN 1-Piperazinepropanamine,
N,N-dimethyl-4-[(4-{(4-{(tetrahydro-2H-pyran-4-
yl)sulfonyl}phenyl)-2-pyrimidinyl)amino}benzoyl)- (9CI) (CA INDEX NAME)




4/11/2003

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 434950-34-2 CAPLUS

CN 4-Piperidinol, 1-[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-35-3 CAPLUS

CN Piperazine, 1-[[3,5-dimethyl-4-isoxazolyl]carbonyl]-4-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-39-7 CAPLUS


CN Piperazine, 3-methyl-1-[[4-[[4-[[4-(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434950-40-0 CAPLUS

CN Piperidine, 4-(1-pyrrolidinyl)-1-[[4-[[4-[[4-(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-41-1 CAPLUS

CN 4-Piperidinol, 1-[4-[[4-[[4-(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-42-2 CAPLUS


CN Piperazine, 1-[[3,5-dimethyl-4-isoxazolyl]carbonyl]-4-[[4-[[4-[[4-(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



Habte


L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A




RN 434950-36-4 CAPLUS

CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-[[4-(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-37-5 CAPLUS

CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[[4-[[4-[[4-(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-38-6 CAPLUS

CN Piperazine, 1-[[4-[[4-[[4-(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 2-A



RN 434950-43-3 CAPLUS

CN Piperazine, 1-acetyl-4-[[4-[[4-[[4-(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-44-4 CAPLUS

CN Piperazine, 1-[[4-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


4/11/2003

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-45-5 CAPLUS

CN Piperazine, 1-(2-ethoxyethyl)-4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434950-46-6 CAPLUS

CN Piperazine, 1-[4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 434950-47-7 CAPLUS

CN Piperazine, 1-acetyl-4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-52-4 CAPLUS

CN Benzamide, N-(4-hydroxycyclohexyl)-4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434950-53-5 CAPLUS

CN Benzamide, N,N-dimethyl-4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




IT 434950-65-9P 434950-68-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of anilinoypyrimidines as JNK pathway inhibitors)

RN 434950-65-9 CAPLUS

CN Benzoic acid, 4-[[4-[(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434950-68-2 CAPLUS

CN Benzoic acid, 4-[[4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 434950-48-8 CAPLUS

CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434950-49-9 CAPLUS

CN Piperazine, 1-methyl-4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434950-50-2 CAPLUS

CN Piperazine, 1-[4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 434950-51-3 CAPLUS

CN 1-Piperazinepropanamine, N,N-dimethyl-4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS (Continued)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

9.49

157.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.30

-1.30

STN INTERNATIONAL LOGOFF AT 14:47:31 ON 11 APR 2003